Selected article for: "case control and systematic search"

Author: Klassen, Stephen A.; Senefeld, Jonathon W.; Johnson, Patrick W.; Carter, Rickey E.; Wiggins, Chad C.; Shoham, Shmuel; Grossman, Brenda J.; Henderson, Jeffrey P.; Musser, James; Salazar, Eric; Hartman, William R.; Bouvier, Nicole M.; Liu, Sean T.H.; Pirofski, Liise-anne; Baker, Sarah E.; van Helmond, Noud; Wright, R. Scott; Fairweather, DeLisa; Bruno, Katelyn A.; Wang, Zhen; Paneth, Nigel S.; Casadevall, Arturo; Joyner, Michael J.
Title: The Effect of Convalescent Plasma Therapy on COVID-19 Patient Mortality: Systematic Review and Meta-analysis
  • Cord-id: j6u9z2ay
  • Document date: 2021_2_17
  • ID: j6u9z2ay
    Snippet: To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from 10 randomized clinical trials (RCT), 20 matched-control studies, two dose-response studies, and 96 case-reports or case-series. Studies published between January 1, 2020 – January 16, 2021 were identified through a systematic search of online PubMed and MEDLINE databases. Random-effects analyses of RCT and matched-control data demonstrated that COVID-19 patients transfused with convale
    Document: To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from 10 randomized clinical trials (RCT), 20 matched-control studies, two dose-response studies, and 96 case-reports or case-series. Studies published between January 1, 2020 – January 16, 2021 were identified through a systematic search of online PubMed and MEDLINE databases. Random-effects analyses of RCT and matched-control data demonstrated that COVID-19 patients transfused with convalescent plasma exhibited a lower mortality rate compared to patients receiving standard treatments. Additional analyses showed that early transfusion (within 3 days of hospital admission) of higher-titer plasma is associated with lower patient mortality. These data provide evidence favoring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized COVID-19 patients.

    Search related documents:
    Co phrase search for related documents
    • abstract title and additional analysis: 1
    • abstract title and low mortality: 1, 2, 3, 4, 5
    • abstract title and low mortality rate: 1
    • active agent and acute respiratory syndrome: 1, 2
    • acute respiratory syndrome and additional analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • acute respiratory syndrome and additional evidence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and administration volume: 1, 2, 3
    • acute respiratory syndrome and long report: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory syndrome and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and low mortality rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and low titer high titer: 1, 2
    • acute respiratory syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • additional analysis and lung damage: 1, 2
    • additional evidence and low mortality: 1, 2, 3
    • additional evidence and lung damage: 1
    • administration volume and lung damage: 1
    • long report and low mortality: 1, 2, 3, 4
    • long report and lung damage: 1
    • low mortality and lung damage: 1, 2, 3, 4